trial

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

NCTId NCT04846868
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 620 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2024-09-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
620 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2021-09-08
Primary completion
2024-09-17
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Iclepertin

Sponsors

Boehringer IngelheimLead Sponsor

Sites

116 total
Garden Grove, United StatesLa Habra, United StatesSan Diego, United StatesSanta Ana, United StatesHartford, United StatesMiami, United StatesMiami, United StatesAtlanta, United StatesBuffalo, United StatesStaten Island, United StatesCincinnati, United StatesNorth Canton, United States

Linked catalysts

1
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schi — primary completion2024-09-17

Facts & assertions

4 sourced
Enrollment
620
Phase
PHASE3
Primary Completion Date
2024-09-17
Status
COMPLETED
relationships
The graph out of here
drug
Iclepertin
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication